Krystal Biotech Inc

Krystal Biotech insider sale: 642 shares sold under a Rule 10b5‑1 plan as routine vesting. The stock’s strong 12.58% monthly gain and 144% YTD rise suggests no downside risk.

Krystal Biotech insider sales raise questions about funding, market‑access timing and competitive positioning in rare‑disease gene‑therapy—what investors need to know.

Krystal Biotech insider trades reveal long‑term confidence in its gene‑therapy pipeline, showing how leadership’s buying and RMAT approval can shape market access and growth prospects.